Skip to main content

Angiodynamics Value Stock - Dividend - Research Selection

Angiodynamics

ISIN: US03475V1017 , WKN: A0B9A5

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Shareholders in AngioDynamics (NASDAQ:ANGO) are in the red if they invested three years ago

2025-04-07
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet

2025-04-07
The average of price targets set by Wall Street analysts indicates a potential upside of 68.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands

2025-04-03
ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.

AngioDynamics Inc (ANGO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

2025-04-03
AngioDynamics Inc (ANGO) reports a robust 9% revenue growth, driven by significant gains in MedTech and mechanical thrombectomy segments, while navigating challenges in reimbursement and cash flow.

Q3 2025 AngioDynamics Inc Earnings Call

2025-04-03
Q3 2025 AngioDynamics Inc Earnings Call

AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates

2025-04-02
AngioDynamics (ANGO) delivered earnings and revenue surprises of 123.08% and 2%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics: Fiscal Q3 Earnings Snapshot

2025-04-02
LATHAM, N.Y. (AP) — AngioDynamics Inc. ANGO) on Wednesday reported a loss of $4.4 million in its fiscal third quarter. On a per-share basis, the Latham, New York-based company said it had a loss of 11 cents.

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

2025-04-02
LATHAM, N.Y., April 02, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025.

AngioDynamics, Inc. 2025 Q3 - Results - Earnings Call Presentation

2025-04-02
The following slide deck was published by AngioDynamics, Inc.

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

2025-04-02
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2025 Earnings Conference Call April 2, 2025 8:00 AM ETCompany ParticipantsJim Clemmer - President & CEOStephen...